Biological therapy of psoriasis

Raja K Sivamani, Genevieve Correa, Yoko Ono, Michael P. Bowen, Siba P Raychaudhuri, Emanual Michael Maverakis

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.

Original languageEnglish (US)
Pages (from-to)161-170
Number of pages10
JournalIndian Journal of Dermatology
Volume55
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

Biological Therapy
Psoriasis
Interleukin-23
Immune System Diseases
Opportunistic Infections
Interleukin-12
Immunosuppressive Agents
Biological Products
Immune System
Lymphoma
Cytokines
T-Lymphocytes
Therapeutics
alefacept
Etanercept
adjuvant P40
Infliximab
Adalimumab
Ustekinumab
efalizumab

Keywords

  • Adverse effects
  • Biologics
  • Psoriasis
  • Therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Biological therapy of psoriasis. / Sivamani, Raja K; Correa, Genevieve; Ono, Yoko; Bowen, Michael P.; Raychaudhuri, Siba P; Maverakis, Emanual Michael.

In: Indian Journal of Dermatology, Vol. 55, No. 2, 01.04.2010, p. 161-170.

Research output: Contribution to journalArticle

Sivamani, Raja K ; Correa, Genevieve ; Ono, Yoko ; Bowen, Michael P. ; Raychaudhuri, Siba P ; Maverakis, Emanual Michael. / Biological therapy of psoriasis. In: Indian Journal of Dermatology. 2010 ; Vol. 55, No. 2. pp. 161-170.
@article{3695e04e691041ffa56b3c525dd9bbd6,
title = "Biological therapy of psoriasis",
abstract = "The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and {"}routine{"} opportunistic infections.",
keywords = "Adverse effects, Biologics, Psoriasis, Therapy",
author = "Sivamani, {Raja K} and Genevieve Correa and Yoko Ono and Bowen, {Michael P.} and Raychaudhuri, {Siba P} and Maverakis, {Emanual Michael}",
year = "2010",
month = "4",
day = "1",
doi = "10.4103/0019-5154.62754",
language = "English (US)",
volume = "55",
pages = "161--170",
journal = "Indian Journal of Dermatology",
issn = "0019-5154",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Biological therapy of psoriasis

AU - Sivamani, Raja K

AU - Correa, Genevieve

AU - Ono, Yoko

AU - Bowen, Michael P.

AU - Raychaudhuri, Siba P

AU - Maverakis, Emanual Michael

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.

AB - The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.

KW - Adverse effects

KW - Biologics

KW - Psoriasis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77952086525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952086525&partnerID=8YFLogxK

U2 - 10.4103/0019-5154.62754

DO - 10.4103/0019-5154.62754

M3 - Article

VL - 55

SP - 161

EP - 170

JO - Indian Journal of Dermatology

JF - Indian Journal of Dermatology

SN - 0019-5154

IS - 2

ER -